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Summary.-Immunoreactive and bioassayable plasma fibronectin (opsonic a2
surface-binding (SB) glycoprotein) was measured during experimental Sarcoma-180
tumour growth in mice. Male C57BL/6 mice were challenged s.c. with 2 x 106 viable
Sarcoma-180 tumour cells and evaluated sequentially in parallel with saline-injected
controls over a 21-day experimental period. Before challenge, immunoreactive
plasma fibronectin was 1050-1150 /Lg/ml. Minimal tumour growth occurred until
6 days after tumour challenge. There was then a rapid increase in primary tumour
size, especially over the7-14-day interval, with a plateau of growth over the 18-21-day
interval. Immunoreactive plasma fibronectin was significantly (P<0.05) raised at
3 and7 days after tumour challenge. A rapid rise (P<0-001) to2816.6 +158*9 ,ug/mlwas
observed at 14 days followed by a modest decline at 21 days. Bioassayable opsonic
activity increased (P<0.05) with the rise in immunoreactive fibronectin 3 and 7 days
after tumour challenge, but the rapid rise in immunoreactive fibronectin over the
7-14-day interval was associated with a significant (P<0.05) fall in bioassayable
opsonic activity. Thus, the rapid rise in immunoreactive plasma fibronectin parallels
the rapid rate of tumour growth, but is associated with a fall in opsonically active
plasma fibronectin. Dissociation between immunoreactive and opsonically active
plasma fibronectin may be mediated by inhibition and/or alteration of circulating
fibronectin during rapid tumour growth. Alternatively, it may reflect increased
release of antigenically related protein (i.e. cell-surface fibronectin) during rapid
tumour growth, which may have limited biological opsonic activity.
MACROPHAGES may represent a primi-
tive and effective cellular anti-tumour
surveillance mechanism (Diller et al., 1963;
Di Luzio, 1975; Hibbs et al., 1972a,b; Levy
& Wheelock, 1974; Old et al., 1960; Stern,
1960). Stimulation of the macrophage
system increases resistance to tumour
challenge (Diller et al., 1963; Stern, 1960)
and macrophage depression decreases re-
sistance to tumour growth. Moreover,
RES phagocytic activity in various strains
of inbred mice correlates with their spon-
taneous incidence of malignant disease
(Stern, 1960).
The reticuloendothelial response to
tumour growth is typically early activa-
tion followed by progressive decline in
RES function as measured by the clear-
ance of gelatin-coated test colloids (Old
et al., 1960, 1961; Saba & Antikatzides,
1975). The importance of opsonic a2
surface-binding (SB) glycoprotein in medi-
ating RE-cell clearance ofgelatinized test
colloids has been documented (Blumen-
stock et al., 1977a; Saba, 1970; Saba et al.,
1978a,b). Determinations of opsonic a2SB
glycoprotein levels by the standard liver-
slice bioassay have demonstrated a decline
following colloid-induced RE blockade
(Saba & Di Luzio, 1969) as well as after
major surgery, burn injury and traumatic
shock (Saba, 1970, 1972; Saba et al.,
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1978a,b; Scovill et al., 1978). Circulating
bioassayable opsonic activity in animals
during tumour growth (Saba & Antikat-
zides, 1975, 1976; Saba & Cho, 1977)
directly correlates withphagocytic activity
as evaluated by colloid clearance. Some-
what analogous clinical studies by Pisano
et al. (1972) as well as Di Luzio (1975) with
the bioassay have demonstrated deficiency
in bioassayable opsonic activity in patients
with advanced malignant disease.
Isolation and characterization ofopsonic
A2SB glycoprotein had led to our dis-
covery that cold-insoluble globulin (CIg)
or plasma fibronectin is identical to
opsonic protein (Saba et al., 1978b;
Blumenstock et al., 1978b). Moreover,
opsonic protein or plasma fibronectin can
now be quantified by electroimmunoassay
in animals (Saba, 1978) and humans
(Blumenstock et al., 1978a). Since de-
ficiency ofopsonic activity as measured by
bioassay during tumour growth could
reflect inhibition of the biological activity
of plasma fibronectin and/or modification
of the circulating molecule, as opposed to
consumptive depletion from the blood as
seen after surgery or trauma (Saba et al.,
1978a,b) we compared levels of circulating
immunoreactive plasma fibronectin as
well as bioassayable opsonic plasma fibro-
nectin (CIg) during tumour growth.
MATERIALS AND METHOI)S
Tumour transplantation. Male C57BL/6
mice weighing 20-25 g were recipients of the
S-180 tumour for both serial transplanta-
tion and individual experiments. Serial
transplantation was done every 18-21 days.
The Sarcoma-180 tumour (S-180) in mice was
used since it is a rapidly growing tumour
which can be readily quantified, and which
produces significant changes in RES phago-
cytic clearance (i.e. early activation followed
by progressive RES decline). The tumour was
excised from the leg under sterile conditions
under ether anaesthesia using a UV trans-
plantation box. The viable periphery of
the tumour was passed through a sterile
170,um-pore microsieve. Tumour cells were
collected in sterile saline, wxNashed twice and
recovered in sterile saline after cenitrifugation
at 1500 rev/min for 10 min at 4°C. Cell con-
centration wvas determined by haemacyto-
metric methods, and cell viability by trypan-
blue exclusion. For both serial transplantation
and experimental studies, recipient mice
received s.c. (right leg) 2 x 106 viable S-180
tumour cells in 0-2 ml of sterile saline. Con-
trols were injected s.c. with 0-2 ml of sterile
saline.
Grozwth curve of tumour. Periodically after
transplantation, the primary tumour size was
determined by calipers (Saba & Antikatzides,
1975). Three orthagonal diameters were used
for the calculation of tumour volume and
tumour weight as originally described
(Schrek, 1935). Tumour volume in cm3 was
estimated 0-5236d3 where d is the mean
tumour diameter as quantified from 3-
dimension measurements. Tumour weight (g)
was then estimated as 1-038 x 0-5236d3,
where the constant 1 038 is used as the
specific gravity of the tumour. These deter-
minations correlate very wvell with actual
tumour weight after careful surgical removal
(Saba & Cho, 1977).
Bioassay ofopson,ic activity. Mouse plasma
was obtained after decapitation from both
control and tumour-bearing C57BL/6 mice.
Blood was collected in plastic centrifuge tubes
supplemented with heparin (100 USP u/ml)
and immediately centrifuged at 5000 rev/min
for 20 min at 4°C to collect plasma. Heparin
is the anticoagulant to use in the liver-slice
bioassay of plasma opsonic activity, since its
presence is a prerequisite for maximal ex-
pression of biological activity (extensively
documented by Saba, 1970; Saba et at., 1966)
and EDTA, citrate or oxalate block the assay
(Ryder et al., 1975). Heparin will, however,
alter the assay if the plasma is stored at 4°C
for extended periods before biological assay,
since it will complex fibronectin and increase
its cryoprecipitation from the plasma. Plasma
opsonic activity was determined by the
standard in vitro liver-slice bioassay (Blumen-
stock et at., 1977b; DiLuzio et al., 1972;
Pisano et al., 1972; Saba, 1972, 1978). The
3.0 ml test medium consisted of Krebs-
Ringer phosphate (pH 7 4), 100 USP u
heparin (Upjohn, Kalamazoo. MI), and the
gelatinized 1311-labelled "RE test lipid
emulsion", as previously described (Saba,
1972; Saba & Antikatzides, 1975). Normal or
experimental plasma for analysis was added
to the incubation flask at a concentration of
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25% (0 75 ml plasma and 2-25 ml buffer).
Each incubation flask, containing a 200-
300mg liver slice, was supplemented with
2-0 mg of the test gelatinized particles and
incubation was conducted with oscillation for
30 min under a gas phase of95% 02 and 5%
CO2 at 37°C in a Dubnoff metabolic shaker.
After incubation, liver-slice uptake of the
test particles was determined by isotopic
assay. Phagocytic uptake was expressed as
the percentage of added colloid dose (%ID)
phagocytosed per 100 mg liver slice. This
method has been previously used in various
experimental and clinical studies (Blumen-
stock et al., 1978a; Di Luzio, 1975; Pisano et
al., 1972; Saba & Antikatzides, 1975; Saba
et al., 1978a,b). Additionally, the use of the
gelatinized "RE test lipid emulsion", as
opposed to inert particles such as gelatin-
coated colloidal gold or gelatinized latex
spheres, produces a higher degree of hepatic
Kupffer-cell ingestion of the test particles
(Hopps & Szakacs, 1967) as opposed to a
high degree of external binding to Kupffer
cells. The correlation between the bioassay
and the immunoassay has been documented
in normal states and after trauma, surgery
and RE blockade (Blumenstock et al., 1977b;
Saba, 1978; Saba et al., 1978a,b; Scovill
et al., 1978).
The 1311 radioactivity was determined
with a Nuclear-Chicago auto gamma crystal
scintillation system equipped with a 2-inch
thallium-activated sodium iodide crystal. All
samples were counted in duplicate with
independent isotope standards in each experi-
ment.
Purification of mouse opsonin by affinity
chromatography.-Blood from donor mice was
collected in 50ml plastic centrifuge tubes and
allowed to clot for 1 h at room temperature.
Serum was collected by centrifugation at
5000 rev/min for 20 min at 4C, and re-
centrifuged at 10,000 rev/min for 20 min at
4W. The isolation procedure used a gelatin-
Sepharose column as previously described to
purifv fibronectin (Engvall & Ruoslahti, 1977)
but with modification and inclusion of
mercaptoethanol (Blumenstock et al., 1979)
to help preserve biological activity as re-
vealed by our previous studies (Blumenstock
et at., 1978a,b). There is a biospecific absorp-
tion of the opsonic protein (cold-insoluble
globulin; plasma fibronectin) to gelatin
(denatured collagen) which appears unique to
this plasma protein. The details of the
affinity purification procedure to obtain bio-
logically active and purified animal and
human opsonic protein has been recently
described in detail (Blumenstock et al., 1979;
Saba & Cho, 1979).
The plasma fibronectin protein (opsonin)
isolated from mice has a high affinity for
gelatin (denatured collagen), will stimulate
macrophage phagocytosis, and has a molecu-
lar structure similar to that ofrat and human
plasma fibronectin, as tested by gradient gel
electrophoresis.
Antiserum preparation.-Antiserum to the
isolated opsonic 0x2SB glycoprotein or plasma
fibronectin was prepared in rabbits as pre-
viously described (Blumenstock et al., 1977b,
1978a). An immunoabsorbent consisting of
glutaraldehyde-cross-linking opsonin-defici-
ent serum can be used for preparation of
monospecific antiserum as previously docu-
mented (Blumenstock et al., 1977b). However,
with affinity chromatography for antigen
isolation, the antiserum developed is often
monospecific, as verified by immunoelectro-
phoresis, which is similar to the results with
human protein (Blumenstock et al., 1979;
Saba et al., 1978b).
Quantification of immunoreactive fibronectin
(opsonic cX2SB glycoprotein).-Electroim-
munoassay or "rocket" immunoelectro-
phoresis was used to measure plasma fibro-
nectin or opsonic protein levels, as previously
described (Blumenstock et al., 1977b; Saba &
Cho, 1979; Saba et al., 1978a). Experimental
serum was assayed for immunoreactive
fibronectin. It was collected via the tail vein
under light ether anaesthesia. Blood samples
were allowed to clot for 60 min at 25WC before
centrifugation to obtain serum. It is recog-
nized that the serum concentration of circu-
lating fibronectin (opsonic glycoprotein) is
consistently less than that of plasma, due to
the incorporation or covalent binding of
plasma fibronectin to fibrin in the presence of
Factor XIII (Mosher, 1976). This difference is
minimal ifthe blood is allowed to clot at room
temperature before collection of the serum
(Mosesson, 1972). All samples for analysis
were carefully handled under such constant
conditions so that serum could be the test
medium used for the immunoassay, as pre-
viously standardized (Blumenstock et al.,
1977b). The serum was diluted to 10% and
10 ,ul was added to each well cut into the
solidified agarose-antiserum solution layer on
the glass plate (5 x 10 inch) used in the
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electroimmunoassay as described (Blumen-
stock et al., 1977b). The samples were then
moved electrophoretically towards the anode
at a voltage of 7-5 V/cm at 4°C for 22 h using
an LKB multiphore system (Blumenstock
et al., 1977b). The plates were washed over-
night, pressed and dried, and subsequently
stained (Blumenstock et al., 1977b). Rocket
heights were used as a quantitative index of
immunoreactive opsonic CX2SB glycoprotein
concentration. Rocket heights were recorded
in millimeters, and a double-reciprocal
standard plot (1/mm vs l/ug opsonic or 1/mm
v8 1% serum) was defined with a DEC-10
computer using protein standards at varying
concentrations. This standard curve was used
to determine serum immunoreactive opsonic
O2SB glycoprotein in,tg/ml (Saba etal., 1978a).
RESULTS
Presented in Fig. 1 is the relationship
between the concentration of fresh mouse
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FIG. 1.-Liver-slice Kupffer-cell phago-
cytosis of the gelatinized 1311-"RE test
lipid emulsion" as a function of plasma
concentration. Each flask was supple-
mented with fresh normal mouse plasma
and diluted with Krebs-Ringer phosphate
to yield a concentration range of 0-66%
plasma. The fibronectin concentration of
this normal mouse plasma was 1132-80 fLg/
ml. Each point represents the mean+s.e.
The observed increase in plasma is highly
significant (P < 0 001).
plasma and uptake ofthe gelatinized "RE
test lipid emulsion" in the liver-slice bio-
assay. Uptake was minimal in the artificial
Krebs-Ringer phosphate buffer in the
absence of plasma. In contrast, with in-
creasing concentration of plasma, there
was a significant (P< 0-0f5) increase in
uptake of the gelatinized 1311 RE test
lipid emulsion with an apparent plateau
beginning at a plasma concentration of
about 66%. The linear portion of the
sensitivity curve for the bioassay with
mouse plasma was -0 75 ml, which
corresponded to a plasma concentration
of 25%. Plasma fibronectin concentration
in such normal mouse plasma is typically
1050-1150 ,ug/ml. It has already been
documented (Blumenstock et al., 1979,
1978b; Saba & Cho, 1979) that the active
factor in plasma responsible for the bio-
assay response is the opsonic a2SB glyco-
protein (plasma fibronectin; CJg). Indeed,
plasma made specifically deficient in
plasma fibronectin by passing via the
affinity column is incapable ofstimulating
the liver-slice bioassay (Blumenstock et
al., 1979; Saba & Cho, 1979) and its
activity can be recovered byreconstitution
with the purified protein (Saba & Cho,
1979). On the basis of these data, 0-75ml
plasma aliquots obtained at varying inter-
vals during the course of S-180 tumour
growth was assayed for its opsonic activity
in this bioassay.
Fig. 2 documents the monospecific
nature of the rabbit antiserum to the
mouse plasma fibronectin, as verified by
immunoelectrophoresis of the antiserum
against normal mouse serum and affinity-
purified mouse opsonic protein (plasma
fibronectin) used to immunize the rabbits.
Single precipitin arcs are evident with
either substrate, confirming the mono-
specificity of the antiserum.
Fig. 3 is a composite presentation ofthe
temporal pattern of immunoreactive
opsonin (fibronectin), bioassayable opsonic
activity and primary tumour growth as a
function of time after tumour challenge.
In this particular study, 120 male mice
were challenged s.c. with 2 x 106 viable
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FIG. 2. Immunoelectrophoresis of normal mouse seium (above) and affinity-purified mouse plasma
fibronectin (below) against rabbit antiserum developed against mouse fibronectin (in trough) to
demonstrate the monospecific nature of the antiserum. Immunoelectrophoresis was conducted at
250V for 95 min. The diffusion time was 48 h at 25°C.
S-180 tumour cells. A group of 50 male
control mice were given an equivalent
volume of sterile saline. Before (0 days)
and at varying intervals (3, 7, 14, 21 days)
after S-180 tumour challenge, 10 animals
from both the control and tumour groups
were randomly selected for a study of bio-
assayable and immunoreactive fibronectin
levels. In parallel, tumour growth was
quantified sequentially at 12 intervals in
the 120 experimental mice for definition
of the growth curve (i.e. 10 mice were
killed at each of the 12 intervals). As can
be seen, there is minimal tumour growth
over the 0-6-day period after trans-
plantation. Thereafter, there is a rapid
growth of the S-180 tumour, especially
over the 7-14-day interval. An apparent
plateau of the size of the primary tumour
was seen by about 18 days.
Bioassayable opsonicfibronectin activity
was quite consistent in control mice
evaluated in groups sequentially through-
out the experiment. In contrast, bio-
assayable opsonic fibronectin activity in
tumour-bearing mice manifested a signifi-
cant rise (P < 0.05) at 3 and 7 days, with a
subsequent downward trend over the
7-14-day interval. Immunoreactive fibro-
nectin in the experimental group was
1186 + 53-2 ,ug/ml at Day 0. This was not
different from the level in the control
group which was 1075 + 28-9 ,ug/ml. It
increased (P < 0.05) in the tumour group
at 7 days after tumour challenge (1321.8
45.8 [g/ml). Thereafter, an increase
(P<0 001) to a maximum of 2816*6+
158-9 jug/ml by 14 days was seen in
parallel with increased tumour size (Fig.
3). This level is higher than we have ever
observed in normal rats, rabbits, sheep
and man, although patients with lung
cancer do have very high immunoreactive
plasma fibronectin levels (Saba & Blumen-
stock, unpublished). Then there is a sig-
nificant (P < 0.05) decline in immuno-
reactive protein by 21 days, but this level
1922*9 + 85 7 Hg/ml) is still above control.
The trend for immunoreactive protein to
begin to decrease by 21 days is temporally
correlated with stabilization of the bio-
assayable level, but the significance ofthis
pattern remains to be determined. These
new findings reflect a clear disparity
between the immunoreactive circulating
opsonin (fibronectin) level and the bio-
assayable circulating opsonin (fibronectin)
level during rapid tumour growth, as
clearly summarized in Fig. 4, which pre-
sents these 2 parameters at the 7- and
14-day interval ofrapid tumour growth.
DISCUSSION
Reticuloendothelial (RE) cells rapidly
phagocytose foreign particles, denatured
protein, tumour cells and effete autologous
tissue debris (Bennett et al., 1964; Cham-
ber & Weiser, 1973; Di Luzio, 1975; Saba,
1970, 1979) and a marked alteration in
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FIGe.3.- Temporal association of circulating
immunoreactive serum fibronectin anve
circulating bioassayble opsonic activity, in
relationship to primary tumontr size in
mice duringh-t180 tumour growth. Mice
received 2 x 106 viable tumour cells s.c. in
0-2 ml saline or an equivalent wtolume of
saline. Analysis was done before and 3, 7,
14 and 21 days after tumour challenge.
The tumour group consisted of 120 male
mice. The control group (lhatched) con-
sisted of 50 mice evaluated in groups of 10
at the 5 sampling times. Mean + s.e. are
presented. The level of immunoreactive
protein at 3, 7, 14 and 21 days was signifi-
cantly (Pt<005) higher than the controls
which were relatively constant.1-0
Tumourweight;,&-,*, Plasmafibronectin.
RE activity occurs in patients with neo-
plastic disease. Such findings, coupled
with the relationship of RES activity to
the growth ofexperimental tumours, have
emphasized the role of the RE,S anti-
tumour defence mechanism (Biozzi et al.,
1958; Diller et al., 1963; Saba, 1970).
Macrophage discrimination between
foreign matter (non-self), altered endo-
genous tissue (altered self) and healthy
indigenous tissue (self) (Saba, 1970) may
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FIGc. 4. Comparative pattern of the im-
munoreactive fibronectin and bioassayable
opsonic activity over the period of rapid
tumour growth between 7 and 14 days
after tumour challenge. The fall in bio-
assayable opsonic activity as well as the rise
in circulating immunoreactive fibronectin
were significant (P < 0 05).
be in part related to opsonic factors (Di
Luzio, 1975; Pisano et al., 1972; Saba,
1970). Enhanced macrophage activity can
be correlated with high opsonic activity,
whilst depression of phagocytosis can be
induced by lowering opsonic activity
(Blumenstock et al., 1977b; Di Luzio et al.,
1972; Saba, 1972; Saba & Di Luzio, 1969).
This sensitivity to opsonic glycoprotein is
manifested by fixed cells such as the
Kupifer cells of the liver, as well as by
mobile RE cells such as peritoneal macro-
phages.
Macrophages are involved in the host's
defence against the growth and spread of
cancer (Biozzi et al., 1958; Di Luzio et al.,
1974; Hibbs et al., 1972a,b; Keller, 1975;
Keller & Hess, 1972; Old et al., 1961). For
example, Halpern et al. (1963) observed a
clear protective effect of BCG infection
against Sarcoma J in mice, which was
correlated with macrophage activation.
Additionally, phagocytosis is greatest in
inbred mice manifesting the lowest inci-
dence of spontaneous tumours, whilst
mice with the greatest incidence of spon-
taneous tumours have lower basal levels
of RE activity (Stern et al., 1967; Stern,
1960).
In the Walker-256 tumour model,
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phasic alterations of RES phagocytic
capacity are correlated with bioassayable
plasma opsonic activity (Saba & Antikat-
zides, 1975). An early rise in plasma opso-
nin activity correlates with hyperphago-
cytosis, whilst later opsonic deficiency
correlates with RES dysfunction. Pisano
et al. (1972) have also demonstrated bio-
assayable opsonic deficiency in patients
with advanced carcinoma. At the time of
our previous studies, the immunoassay for
opsonic protein was not available, so it
was not possible to determine whether
bioassayable opsonic deficiency was due
to depletion of plasma protein from the
circulation or inhibition of its biological
activity in the plasma. The fact that
circulating gelatin-coated particles
(Blumenstock et al., 1977b) or viable
tumour cells such as leukaemic leucocytes
will readily decrease opsonic activity (Di
Luzio et al., 1972) as well as the observa-
tion that purified 1251 opsonic protein in
the blood is sequestered into a site of
tissue injury, suggested a depletion de-
ficiency. However, the possibility that the
tumour may depress opsonic activity was
apparent in view of the rapid recovery of
bioassayable opsonic activity in cancer
patients after surgical removal of their
tumour (Di Luzio, 1975; Pisano et al.,
1972).
The concept of increased tumour im-
munity after nonspecific macrophage
activation has been emphasized (Hibbs
et al., 1972b; Keller, 1975, 1976). Macro-
phage activation has been correlated with
suppression of tumour growth (Keller,
1975; Keller & Hess, 1972) and may
reflect an increased participation ofmacro-
phages in the rejection process via a non-
specific or specific process (Di Luzio, 1975;
Keller, 1975; Levy & Wheelock, 1974).
Macrophage phagocytosis of tumour cells
has been demonstrated, and histiocytic
activation associated with anti-tumour
defence has experimental support (Journey
& Amos, 1962; Keller, 1975; Levy &
Wheelock, 1974). Macrophages can induce
lvsis of tumour cells, and such lytic
ability appears to be related to contact-
induced destruction and associated release
of lysosomal enzymes (Hibbs, 1974;
Journey & Amos, 1962; Keller, 1973;
Keller & Hess, 1972). Thus, the anti-
tumour immunity expressed by macro-
phages may be related to recognition of
abnormal cells and phagocytic destruc-
tion, as well as to extracellular cytotoxic
and cytostatic mechanisms (Bennett et
al., 1964; Keller, 1975).
Biochemical characterization (Saba et
al., 1978b; Blumenstock et al., 1978b) of
opsonic A2SB glycoprotein has led to our
discovery that cold-insoluble globulin
(Mosesson, 1972) also called plasma fibro-
nectin (Yamada & Olden, 1978) is identical
to opsonic protein. Plasma fibronectin is
antigenically related to an adhesive-cell-
associated glycoprotein known as cell-
surface fibronectin, large external trans-
formation sensitive (LETS) protein (Hynes
et al., 1978), fibroblast surface antigen
(Rouslahti & Vaheri, 1975) and cell-
attachment factor (Yamada & Olden,
1978). Cell-surface fibronectin is found on
vascular endothelial cells (Jaffe & Mosher,
1978) as well as fibroblasts in tissue culture
(Rouslahti & Vaheri, 1975). We have also
shown it on the surface of macrophages,
and RE cells may be a major site of
opsonic protein production, as originally
speculated (Saba, 1970). It appears essen-
tial for adherence of fibroblasts to a
collagenous substrate and is lost from the
cell surface after oncogenic transformation
(Hynes et al., 1978; Yamada & Olden,
1978). Such loss is associated with altered
cell adhesion, morphology and cell inter-
action (Yamada & Olden, 1978). This
suggests that altered cell-surface fibro-
nectin might lead to decreased attachment
and increased metastatic potential. How-
ever, others such as Der & Stanbridge
(1978) suggest that there is no correlation
between decreased expression of cell-
surface LETS protein and increased
tumorigenicity of specific cell lines.
Yamada & Kennedy (1979) have shown
that fibroblast cellular fibronectin and
plasma fibronectin are very similar but
may not be identical. While the plasma
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form is active in stimulating phagocytosis
(Blumenstock et al., 1979; Saba & Cho,
1979) it has yet to be proved whether or
not the cell-surface protein in its native
form and configuration has such biological
activity. Cell-surface fibronectin may
primarily participate as an adhesive
glycoprotein, while the more soluble
plasma and lymph fibronectin may partici-
pate as an opsonic molecule in augmenting
macrophage host-defence mechanisms
(Saba&Jaffe, 1980). Injuredsepticpatients
demonstrate immunoreactive and bio-
assayable opsonic fibronectin deficiency
correlated with failure ofhost defence and
organs (Saba et al., 1978a,b; Scovill et al.,
1978). Infusion of cryoprecipitate which is
rich in opsonic ac2SB glycoprotein will
reverse opsonic deficiency in such patients
(Saba et al., 1978a,b; Scovill et al., 1978)
with marked improvement in cardio-
vascular, pulmonary and host defence
function.
In the present study, the separation of
immunoreactive and bioreactive fibro-
nectin with rapid tumour growth may be
of importance to macrophage anti-tumour
defence mechanisms during cancer. Before
the immunoassay became available, it was
assumedthatdeficiency ofopsonic activity
during advanced cancer represented de-
pletion as observed after RE blockade
(Blumenstock et al., 1977a; Saba & Di
Luzio, 1969) or surgery and trauma (Saba
et al., 1978a,b; Scovill et at., 1978). Con-
firmation of depletion after blockade
(Blumenstock et al., 1977b) or trauma
(Saba & Cho, 1979; Saba et al., 1978b) has
been obtained by immunoassay, but the
present data suggest an alternate mech-
anism during cancer. Tumour growth and
spread may produce either inhibition and/
or proteolytic destruction of biologically
active plasma fibronectin, resulting in
immunoreactive fragments without bio-
logical activity.
Fibronectin may be bound in theplasma
to circulating entities and thus detectable
by immunoassay but undetectable by
bioassay. An alternate explanation may
be related to the antigenic similarities, but
potentially subtle functional differences
between cell-surfacefibronectinandplasma
fibronectin (Saba & Jaffe, 1980). Thus the
great increase in immunoreactive protein
may reflect abnormal release of cell-
surface fibronectin (or fragments of mole-
cule) which are antigenically related, but
not as active for stimulating phago-
cytosis. Such fragments may also com-
petitively inhibit the bioassay. The release
of LETS with malignant transformation
(Hynes et al., 1978) the antigenic cross-
reactivity of cell-surface and plasma fibro-
nectin (Yamada & Olden, 1978; Ruoslahti
& Vaheri, 1975) and the subtle differences
between the cell-surface and the plasma
form of the protein (Yamada & Kennedy,
1979) all indirectly support this concept.
Whilst the basis for the "blunting" of
the bioassayable opsonic activity during
tumour growth and spread can only be
speculated on, this may compromise
macrophage anti-tumour defence activity.
Moreover, the possibility that an acute
rise in immunoreactive non-opsonically
active fibronectin may indirectly serve as
a marker for rapid tumour growth war-
rants investigation.
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